AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab significantly extended overall survival in a Phase III trial of ...

The Cambridge, England-based pharmaceutical company said the recommendation, from the Committee for Medicinal Products for Human Use of the European Medicines Agency, covers Klygefa as an add-on to ...

AstraZeneca said on 18 September 2026 that the US Food and Drug Administration had accepted the Biologics License Application ...

A gym boss and a "soldering genius" are among the non-scientists working at the park.

Big Picture Bio Ltd., has been founded to identify, design and optimize promising cancer combination therapies, using a generative world model to understand how tumors, immune cells and surrounding ...

The latest company to spin out of a Stanford Medicine lab is a biotech undertaking with 37,000 employees—and none of them are ...

All three companies’ near- and long-term emissions targets have been validated by the Science Based Targets initiative (SBTi) ...

Trastuzumab deruxtecan is a HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The treatment combines ...

New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 30 million equity ...

Sir Keir Starmer’s decision to invite Sir Pascal Soriot, AstraZeneca’s chief executive, to Beijing at the beginning of the year was a textbook piece of modern diplomacy.

Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDTCompany ParticipantsBrett Monia ...